around puberty and the incidence within Europe ranges from 40 to four cases/100 000/year along a north-south gradient from Scandinavia to Greece, punctuated with occasional 'hot-spots' such as Sardinia.' In the UK, the incidence is estimated at some 16 cases/100 000/year and appears to be rising.
Type 1 diabetes arises on a distinct genetic background. While the disease may be polygenic, attention has focused on the HLA system; some class II alleles (HLA DR3 and DR4 serotypes, or genes encoding DQ molecules such as DQAI*0301/DQBI*0302) impart a high risk of developing diabetes, while others (DR2, DQAl*0102/DQB1*0602) provide protection. 3 Genetically identical (monozygotic) twins of type 1 diabetic patients carry a higher relative risk (approximately 230) of becoming diabetic than does an individual possessing any one of the HLA markers described above, yet only one third of such twins will develop the disease.45 In other words, environmental factors must have an important influence on the development of the disease.
The detection of a mononuclear cell (lymphocyte and macrophage) infiltrate within and around islet remnants at diagnosis indicates that the immune system has a role in the pathogenesis of the disease.6 Circulating islet-specific autoantibodies,7 abnormal distributions of immunoregulatory89 and activated T lymphocytes,'0"1 and evidence of T cells reactive with islet components at the onset of diabetes are consistent with this hypothesis. 12 13 Thus Immunological abnormalities in type 1 diabetes Several abnormalities, in both the cellular and humoral arms of the immune system, have been identified in newly diagnosed patients with type 1 diabetes in the last 20 years. Autoantibodies include islet cell antibodies,'4 insulin autoantibodies,'5 antibodies to a 64 kD islet protein'6 (now identified as the enzyme glutamic acid decarboxylase"'), and antibodies to 50 kD and 37 kD tryptic fragments of islet proteins. 18 Activated T lymphocytes, particularly those expressing CD8 (cytotoxic/suppressor phenotype), are typically present in the islet of Langerhans cellular infiltrate seen at diagnosis of type 1 diabetes. '1 Islets from newly diagnosed diabetic patients are rarely accessible for study, but changes in circulating lymphocyte subsets of activation and function constitute some of the best characterised cellular immune abnormalities in type 1 diabetes.20 Circulating levels of activated T lymphocytes, expressing the class II HLA molecule HLA-DR'°" or the interleukin-2 receptor,2' are increased at diagnosis of type 1 diabetes, indicating involvement of the cellular immune system in the autoimmune responses, and paralleling the characteristics of the islet infiltrate.
Changes in the immune system associated with type 1 diabetes could result from the genetic susceptibility to the disease, the metabolic changes of diabetes, or be part of the immune process leading to destruction of the islet ,B cells. Twin studies enable us to discriminate between these possibilities. Since the 1970s, we have followed up a cohort of non-diabetic twins, enrolled into the study soon after the diagnosis of diabetes in their co-twin. Prospective studies identify prediabetic and diabetes resistant twins so that the two groups can be compared.
Studies on prediabetic twins: predicting the onset In a prospective study, following the design outlined and using a cohort of 20 twins of whom half became diabetic, immune abnormalities were highly prevalent in the prediabetic twins.22 Islet cell antibodies were detected in nine of the 10 prediabetic twins in the earliest sample analysed and persisted in eight until diagnosis of diabetes: if present, they tended to be of high titre. Cellular immune studies on the same cohort demonstrated that all prediabetic twins had high circulating levels of activated T cells in the first sample tested. T cell activation was increased in both the CD4 (helper/inducer) and CD8 (cytotoxic/suppressor) populations. 23 As with islet cell antibodies, cellular activation persisted in nine of the 10 twins throughout the prediabetic period.
From a larger cohort of58 twins, samples were obtained on a single occasion and analysed for the presence of antibodies to islet cells, glutamic acid decarboxylase, and the 50 and 37 kD islet tryptic fragments.24 Twelve of the 58 twins became diabetic, and the majority of prediabetic twins (67-75%) had each of these different antibodies and all 12 had at least one of the antibody specificities.
Thus, the characteristic of cellular and humoral immune abnormalities in the prediabetic period was the combinations of intensity, number and persistence. This provided a powerful predictor ofdiabetes in twins in that the presence of increased levels of activated T cells and islet cell antibodies or insulin autoantibodies detected on two consecutive occasions has a positive predictive value for diabetes of 100%.22
Studies on twins remaining non-diabetic: identifying protection Twins remaining non-diabetic six years or more from the diagnosis of the index twin constitute a low risk group highly unlikely to develop diabetes. Interestingly, however, immune abnormalities, both cellular and humoral, were present in some of these twins.22 In contrast to prediabetic twins, islet cell antibodies were detected in only three of the 10 twins during follow up and were transient and at low titres. Six of the 10 twins remaining non-diabetic also had increased levels of activated T cells initially, but these were only detected on two further occasions during the follow up, that is, they did not persist. Analysis of the functional phenotype of the activated cells demonstrated a lack of activation in the CD8 population in contrast to prediabetic twins.23 In a larger cohort, in which 46 of 58 twins remained non-diabetic, antiglutamic acid decarboxylase, anti-50 kD, and anti-37 kD antibodies were detected in only 13%, 15%, and 2% respectively.24
Protection from diabetes appears, therefore, to be conferred by default: twins remaining non-diabetic were characterised by the absence, low titre or transience of isletspecific antibodies, and the presence of activated T cells of the helper, but not the cytotoxic phenotype.
Significance of twin studies Twin studies such as these allow the identification of immune markers, detectable in the peripheral blood, which may predict the onset of the disease with considerable power, or equally indicate that a twin is safe from developing diabetes. These studies form a test bed for potential immune markers, some of which can be applied to population screening. Screening has become a desirable goal as the potential for therapeutic intervention, perhaps based on immunotherapy, to prevent diabetes has become a concrete possibility.2"
In addition, twin studies have aided in defining the nature of the process which leads to type 1 diabetes. Our studies indicate that this process is initiated several months or years before the clinical diagnosis of diabetes. The destructive mechanisms, probably involving both activated CD4 and CD8 T lymphocytes, must persist in order to mediate irreparable islet damage. In contrast to immune responses to pathogens, this autoimmune response is less effective, taking several years to destroy its target. In some twins who remain disease free an immune response directed against the islets is also present, though this is mild and transient. Thus, the process leading to diabetes need not be an 'all-or-none' phenomenon. Further studies are required to determine the features of such diabetes resistance and, in particular, whether such a state can be induced in high risk individuals with persistent, high level cellular and humoral immune changes.
Summary
Diabetes is a multifactorial disease, the pathogenesis of which involves participation of the host immune system in , cell destruction. Studies on identical twins offer the opportunity to define genetic and non-genetic factors which may contribute to susceptibility to the disease. Our own work indicates that the number and nature, as well as the intensity and persistence of immune abnormalities of cellular and humoral immune responses can be powerful predictors of the disease and also identify twins who have a degree of protection from the disease. 
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